Research graph
References from Scottish Airways Research Network (SARN) Delphi Consensus on pre-biologic assessment, clinical remission and post-remission management in severe asthma. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Precision Medicine for Asthma: Tailored to its Severity and Endotype/Phenotype
10.4168/aair.2026.18.1.19 · 2026 · External reference
An expert consensus framework for asthma remission as a treatment goal
10.1016/j.jaci.2019.12.006 · 2020 · External reference
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis
10.1016/s2213-2600(24)00293-5 · 2025 · External reference
A multidisciplinary team case management approach reduces the burden of frequent asthma admissions
10.1183/23120541.00039-2016 · 2016 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Delphi methodology in healthcare research: How to decide its appropriateness
10.5662/wjm.v11.i4.116 · 2021 · External reference
Delphi methodology in health research: how to do it?
10.1016/j.eujim.2015.07.002 · 2015 · External reference
Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies
10.1016/j.jclinepi.2013.12.002 · 2014 · External reference
Unresolved reference
External reference
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma
10.1378/chest.125.4.1378 · 2004 · External reference
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma
10.1183/13993003.00413-2021 · 2021 · External reference
Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma
10.1016/j.jaip.2019.08.050 · 2020 · External reference
Unresolved reference
External reference
Tiotropium in asthma poorly controlled with standard combination therapy
10.1056/nejmoa1208606 · 2012 · External reference
Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
10.1007/s41030-023-00234-y · 2023 · External reference
Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy
2026 · External reference
Exhaled nitric oxide: a predictor of steroid response
10.1164/rccm.200411-1498oc · 2005 · External reference
Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta-Analysis
10.1111/all.70031 · 2026 · External reference
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
10.1016/s2213-2600(21)00226-5 · 2021 · External reference
Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthma
10.1016/j.jaci.2024.11.024 · 2025 · External reference
The Role of Biologics in Reducing Mucous Plug Burden in Asthma
10.1111/all.70197 · 2026 · External reference
Biologics and airway remodeling in asthma: early, late, and potential preventive effects
2024 · External reference
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
10.1056/nejmoa2401304 · 2024 · External reference
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
10.1016/s2213-2600(24)00409-0 · 2025 · External reference
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
10.1056/nejmoa2413181 · 2025 · External reference
Impact of Smoking on Biological Treatment Response in Patients From the German Severe Asthma (GAN) Registry
10.1016/j.jaip.2025.01.005 · 2025 · External reference
Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register
10.1016/j.jaip.2023.10.012 · 2024 · External reference
Biologic outcomes in severe asthma patients by smoking status: evidence from SHARP
10.1093/ajrccm/aamag473 · 2026 · External reference
Asthma remission: what is it and how can it be achieved?
10.1183/13993003.02583-2021 · 2022 · External reference
FEV(1) Minimum Important Difference versus Minimal Detectable Difference? In Search of the Unicorn
10.1164/rccm.202012-4322le · 2021 · External reference
Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma
10.1016/j.jaci.2022.10.028 · 2023 · External reference
Efficacy of biologic therapy on airway hyperresponsiveness in asthma
10.1016/j.anai.2023.02.016 · 2023 · External reference
New Perspectives on Effects of Biologics on Mannitol Airway Hyperresponsiveness
10.1111/cea.70221 · 2026 · External reference
Unresolved reference
External reference
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
10.1016/s0140-6736(23)02284-5 · 2024 · External reference
Development and validation of a questionnaire to measure asthma control
10.1034/j.1399-3003.1999.14d29.x · 1999 · External reference
The impact of dysfunctional breathing on the assessment of asthma control
10.1016/j.rmed.2016.12.008 · 2017 · External reference
OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial
10.1183/13993003.00404-2024 · 2024 · External reference
Feasibility of a 50% Dosing Interval Extension of Anti-IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study
10.2147/jaa.s567136 · 2026 · External reference
How to Adjust Asthma Management Once Asthma Is Controlled on Long-Term Biologic Therapy
10.1016/j.jaip.2025.05.031 · 2025 · External reference
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
10.1016/s1542-3565(04)00238-1 · 2004 · External reference
